MAbSilico

Curated by Signal

Developer of biomarker and therapeutic antibodies

Overview

MAbSilico (spinoff of CNRS) is developing biomarker and therapeutic antibodies combining artificial intelligence and machine learning technology. The company uses AI-driven tools and a proprietary technique for designing and developing antibodies. The company has developed MAbTope, a docking-based method to model the antibody structure.

Key facts

Founded: 2016
Headquarters: Nouzilly, France
Stage: Sign up to view
Industry: Life Sciences Technology

Business model

3 products and services: Sign up to view

Contact

Email: Sign up to view

More on Vanberra Signal

Members only

Business overviewCore metrics and financials PeopleLeadership and key people Similar companiesPeers and competitors Deep AnalysisAI-generated strategic report

Competitors & similar companies

More Life Sciences Technology companies

Gynov
Developer of pharmaceuticals and dietary supplements for women health
Life Sciences TechnologyBordeaux, France
Next GS
Open source genome scaffolding software
Life Sciences TechnologyFrance
GenoScreen
Provider of genomic services and innovative solutions in genomics
Life Sciences TechnologyLille, France

About MAbSilico

What does MAbSilico do?

MAbSilico (spinoff of CNRS) is developing biomarker and therapeutic antibodies combining artificial intelligence and machine learning technology.

Where is MAbSilico headquartered?

MAbSilico is headquartered in Nouzilly, France.

When was MAbSilico founded?

MAbSilico was founded in 2016.

Which sector is MAbSilico in?

MAbSilico operates in Life Sciences Technology.

Who are MAbSilico's competitors?

Companies similar to MAbSilico include Gynov, Next GS, and GenoScreen.